E. coli ´s fight against TYROnny: Designing a bacterial strain to tackle tyrosinemia type 1
Tyrosinemia type 1 (HT-1) is a rare autosomal recessive disease caused by a deficiency of fumarylacetoacetate hydrolase (FAH)1,2 and occurs in approximately 1 in 100,000 newborns3. The lack of FAH leads to an increase of intermediary products when degrading the amino acids phenylalanine and tyrosine to fumarate and acetoacetate2 (Figure 1a). Next to the name-giving increase of tyrosine levels in the sera of patients suffering from this disease, an elevation of fumarylacetoacetate (FAA), the direct substrate of FAH, can be detected2 (Figure 1b). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 23, 2023 Category: Gastroenterology Authors: J öran Lücke, Samuel Huber Tags: Editorial Source Type: research
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes
The long-term impact of alcohol-related public health policies (PHP) on disease burden is unclear. We aimed to assess the association between alcohol-related PHP and alcohol-related health consequences. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 20, 2023 Category: Gastroenterology Authors: Luis Antonio D íaz, Eduardo Fuentes-López, Francisco Idalsoaga, Gustavo Ayares, Oscar Corsi, Jorge Arnold, Macarena Cannistra, Danae Vio, Andrea Márquez-Lomas, Carolina Ramirez-Cadiz, María Paz Medel, María Hernandez-Tejero, Catterina Ferreccio, Mari Tags: Research Article Source Type: research
Redox-Sensitive High-Mobility Group Box-1 Isoforms Contribute To Liver Fibrosis Progression And Resolution In Mice
High-mobility group box-1 (HMGB1) significantly increases and undergoes post-translational modifications (PTMs) in response to liver injury. Since oxidant stress plays a major role in liver fibrosis and induces PTMs in proteins, we hypothesized that redox-sensitive HMGB1 isoforms contribute to liver fibrosis progression and resolution. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 19, 2023 Category: Gastroenterology Authors: Xiaodong Ge, Romain Desert, Fernando Magdaleno, Hui Han, Zhuolun Song, Sukanta Das, Dipti Athavale, Wei Chen, Ines Barahona, Daniel Lantvit, Hui Chen, Sunil Hwang, Natalia Nieto Tags: Research Article Source Type: research
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among NAFLD patients and providers. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 17, 2023 Category: Gastroenterology Authors: Zobair M. Younossi, Saleh A. AlQahtani, Khalid Alswat, Yusuf Yilmaz, Caglayan Keklikkiran, Jes ús Funuyet-Salas, Manuel Romero-Gómez, Jian-Gao Fan, Ming-Hua Zheng, Mohamed El-Kassas, Laurent Castera, Chun-Jen Liu, Vincent Wai-Sun Wong, Shira Zelber-Sagi Tags: Research Article Source Type: research
Genomics on the road to functional cure of hepatitis B
Hepatitis B virus (HBV) infection can be prevented, and the World Health Organization aims to eliminate HBV as a public health threat by 2030.1,2 However, mortality from HBV exceeds that from malaria and HIV, and is projected to rise sharply because an estimated 296 million persons already are living with chronic hepatitis B (PLWHB).1 –3 There are treatments for PLWHB, but none cures more than 10%.4,5 Identifying which of the 296 million will be cured by existing treatments and finding new cures for the rest are among the most important challenges in hepatitis elimination. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 17, 2023 Category: Gastroenterology Authors: Ashwin Balagopal, David L. Thomas Tags: Editorial Source Type: research
When you eat and when you sleep matters: circadian dysfunction revealed as a direct hepatic carcinogen in a humanized mouse model
Yes, WHEN you sleep and WHEN you eat matters, and it has a direct impact on the health of your liver. Abundant literature over the last two decades supports this tenet 1 –7. Certainly, multiple indirect evidences ranging from epidemiological data to mouse models of circadian gene deficiency or induction of circadian disruption, have been provided on the role of circadian rhythm disturbances, including jet-lag, shift work and unhealthy lifestyle, in the development of chronic liver disease and hepatocellular carcinoma (HCC). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 17, 2023 Category: Gastroenterology Authors: Carmen Berasain Tags: Editorial Source Type: research
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
There is a knowledge gap in understanding mechanisms of resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) and a need for novel therapeutic strategies to overcome it. We investigated mechanisms of acquired resistance to FGFRi in patients with FGFR2-fusion-positive cholangiocarcinoma (CCA). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Timothy P. DiPeri, Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott, Michael P. Kahle, Charnel C. Byrnes, Huiqin Chen, Sunyoung S. Lee, Abdel-Baset Halim, Hiroshi Hirai, Volker Wacheck, Lawrence N. Kwong, Jordi Rodon, Milind Javle, Tags: Research Article Source Type: research
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH
Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions, fueled by the obesity pandemic. In NAFLD, monocytes infiltrate visceral adipose tissue that promote local and hepatic inflammation. It however remains unclear what drives inflammation and how the immune landscape in adipose tissue differs across the NAFLD severity spectrum. We aimed to assimilate the adipose tissue macrophage (ATM) heterogeneity in a NAFLD cohort. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Markus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, Paola Brescia, Alessandra Silvestri, Matthias Lannoo, Ellen Deleus, Joris Jaekers, Halit Topal, Baki Topal, Tessa Ostyn, Marie Wallays, Lena Smets, Lukas Van Melkebeke, Anetta H ärtlova, Tania Roskams, Tags: Research Article Source Type: research
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Immune-related liver injury(irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors(ICIs). We aimed to compare incidence, clinical characteristics and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma(HCC) versus other solid tumours. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Ciro Celsa, Giuseppe Cabibbo, Claudia AM Fulgenzi, Bernhard Scheiner, Antonio d ’Alessio, Giulia F. Manfredi, Naoshi Nishida, Celina Ang, Thomas U. Marron, Anwaar Saeed, Brooke Wietharn, Matthias Pinter, Jaekyung Cheon, Yi-Hsiang Huang, Pei-Chang Lee, Tags: Research Article Source Type: research
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
The hepatic accumulation of excess triglycerides is a seminal event in the initiation and progression of non-alcoholic fatty liver disease. Hepatic steatosis occurs when the hepatic accrual of fatty acids by uptake from the plasma and by de novo lipogenesis (DNL) is no longer balanced by rates of fatty acid oxidation and by secretion as VLDL triglycerides. Accumulating data indicate that increased rates of DNL are central to the development of hepatic steatosis in NAFLD. Whereas the main drivers in NAFLD are transcriptional, owing to both hyperinsulinemia and hyperglycemia, the effectors of DNL are a series of well charact...
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: William P. Esler, David E. Cohen Tags: Review Source Type: research
In memoriam: Hanns-Ulrich Marschall (1954-2023)
On August 1, 2023 Professor Hanns-Ulrich Marschall, Professor of Clinical Hepatology, Sahlgrenska Academy, University of Gothenburg, passed away from cancer. He was an outstanding physician, clinical scientist and educator. He was an internationally leading expert in bile acid metabolism and cholestasis and will be greatly missed by many colleagues around the world (Fig. 1). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Catherine Williamson, Fredrik B äckhed, Peter Fickert Tags: Obituary Source Type: research
Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module
Metabolic dysfunction-associated steatohepatitis (MASH) is linked to insulin resistance and type II-diabetes and marked by hepatic inflammation, microvascular dysfunction, and fibrosis, impairing liver function and aggravating metabolic derangements. Liver homeostatic interactions disrupted in MASH are still poorly understood. We aimed to elucidate the plasticity and changing interactions of non-parenchymal cells associated with advanced MASH. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Sofie M. Bendixen, Peter R. Jakobsgaard, Daniel Hansen, Kamilla H. Hejn, Mike K. Terkelsen, Frederik A. Bjerre, Annemette P. Thulesen, Niels G. Eriksen, Philip Hallenborg, Yana Geng, Trine V. Dam, Frederik T. Larsen, Charlotte W. Wernberg, Janusa Vijayath Tags: Research Article Source Type: research
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
There is a knowledge gap in understanding mechanisms of resistance to FGFR inhibitors (FGFRi) and a need for novel therapeutic strategies to overcome it. We investigated mechanisms of acquired resistance to FGFRi in FGFR2-fusion-positive cholangiocarcinoma (CCA) patients. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 14, 2023 Category: Gastroenterology Authors: Timothy P. DiPeri, Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott, Michael P. Kahle, Charnel C. Byrnes, Huiqin Chen, Sunyoung S. Lee, Abdel-Baset Halim, Hiroshi Hirai, Volker Wacheck, Lawrence N. Kwong, Jordi Rodon, Milind Javle, Tags: Research Article Source Type: research
An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1
In this study, we aimed to construct an engineered bacterium capable of reprogramming host metabolism and thereby provide a potential alternative approach for the treatment of HT1. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 10, 2023 Category: Gastroenterology Authors: Peng Gu, Li Xie, Tao Chen, Qin Yang, Xianglong Zhang, Ruofan Liu, Jiayin Guo, Rongjuan Wei, Dongping Li, Yong Jiang, Ye Chen, Wei Gong, Peng Chen Tags: Research Article Source Type: research
Stop using the misidentified cell line LO2 as a human hepatocyte
Recently, we read the article by Song et al. in the Journal of Hepatology.1 Using cellular and animal models, the authors concluded that B. pseudolongum protected against non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC) by secreting the antitumor metabolite acetate through the gut-liver axis, and thus, s uggested that B. pseudolongum is a potential probiotic for NAFLD-HCC prevention. Undoubtedly, the results of this study are very promising regarding a novel probiotic for the potential prevention and treatment of NAFLD-HCC in humans. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 9, 2023 Category: Gastroenterology Authors: Ting Shao, Yue-Lei Chen Tags: Letter to the Editor Source Type: research
